SEP-4199
Chemical compound
From Wikipedia, the free encyclopedia
SEP-4199, also known as non-racemic amisulpride, is a non-racemic form of amisulpride which is under development for the treatment of bipolar depression.[1][2][3] It is taken by mouth.[1]
- Investigational
- 71675-90-6 (R)
71675-92-8 (S)
Aramisulpride (R)-amisulpride | |
 Esamisulpride (S)-amisulpride | |
| Clinical data | |
|---|---|
| Other names | SEP4199; Non-racemic amisulpride; Aramisulpride/esamisulpride; Esamisulpride/aramisulpride |
| Routes of administration | Oral[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H27N3O4S |
| Molar mass | 369.48 g·mol−1 |
It was developed to have higher binding affinity for the serotonin 5-HT7 receptor and lower affinity for the dopamine D2 receptor compared to conventional racemic amisulpride.[1][3][4][5] It contains the (R)- and (S)-enantiomers of amisulpride (aramisulpride and esamisulpride) in an 85:15 ratio rather than a 50:50 ratio.[3] The modification is hoped to give the compound improved effectiveness and fewer side effects.[3][6]
If approved, it would be the first form of amisulpride approved in the United States for psychiatric indications.[5] It is in phase 3 clinical trials for bipolar depression as of December 2023.[1][7] Its development was reported to have been discontinued in certain countries including the United States and Japan in November and December 2023.[1] Sources are conflicting on whether it remains in development.[1][2]
See also
- N-Methylamisulpride (LB-102)